Saturday 17 October 2026
Export AXSM’s income statement to Excel — free account
Axsome Therapeutics, Inc.
AXSM Healthcare Biotechnology
Axsome Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $638.5 million, up 65.5% from fiscal 2024. In the quarter to June 2026, revenue grew 45.5%, EPS fell 2.06%, free cash flow fell 2.98% and total debt rose 4.66%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
157.14
4.65
−2.87%
Follow AXSM
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
10.82 | 14.23 | 12.22 | 16.33 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
5,808.00 | (487.10) | (418.04) | (384.77) | |
P/B ratio |
82.40 | 102.90 | 158.53 | 152.20 | |
Price to Tangible BV |
310.61 | 254.26 | 2,405.15 | 373.97 | |
EV/Sales |
10.46 | 13.92 | 11.96 | 16.08 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(58.17) | (95.13) | (119.79) | (175.23) | |
EV/FCF |
(57.92) | (94.64) | (119.35) | (173.53) | |
Quick Ratio |
1.45 | 1.44 | 1.27 | 1.30 | |
Current Ratio |
1.57 | 1.55 | 1.39 | 1.43 | |
Net Debt/EBITDA |
4.66 | 8.20 | 2.98 | 4.14 | |
Debt/Assets |
18.28% | 17.68% | 17.33% | 16.68% | |
Debt/Equity |
1.66 | 1.38 | 2.27 | 1.52 | |
Asset Turnover |
0.91 | 1.01 | 1.08 | 1.11 | |
Operating CF/Net income |
(0.02) | 0.65 | 0.32 | 0.64 | |
Capex/Depreciation |
(0.02) | (0.03) | (0.05) | (0.15) | |
Interest Coverage |
(41.17) | (23.00) | (53.47) | (32.24) | |
Research and Development Expense of Revenue |
23.49% | 24.89% | 27.55% | 21.17% | |
Selling, General and Administrative Expense of Revenue |
87.86% | 86.38% | 96.75% | 95.31% | |
Intangible Assets out of Total Assets |
0.08 | 0.08 | 0.07 | 0.06 | |
Share Based Compensation of Revenue |
13.51% | 11.60% | 12.26% | 12.43% | |
Graham Net Nets |
0.00 | 0.00 | (0.01) | 0.00 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(3.85%) | (2.02%) | (2.21%) | (1.53%) | |
Free Cash Flow Yield |
(1.67%) | (1.03%) | (0.82%) | (0.57%) | |
Revenue per Share |
3.42 | 3.94 | 3.73 | 4.22 | |
Operating CF per Share |
0.02 | (0.37) | (0.40) | (0.64) | |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.01) | |
Free Cash Flow per Share |
0.02 | (0.38) | (0.41) | (0.64) | |
Cash per Share |
6.50 | 6.49 | 5.96 | 6.17 | |
Shareholders Equity per Share |
1.47 | 1.77 | 1.07 | 1.61 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.47 | 1.77 | 1.07 | 1.61 | |
Free Cash Flow |
0.99 | (18.72) | (20.82) | (33.40) | |
Working Capital |
205.05 | 210.15 | 172.00 | 196.12 | |
Capital Expenditures |
(0.06) | (0.07) | (0.12) | (0.45) | |
Net Current Asset Value |
(30.18) | (12.52) | (47.81) | (21.57) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
160.30 | 183.23 | 206.23 | 238.14 | |
Average Payables |
59.24 | 68.77 | 96.18 | 85.30 | |
Average Inventory |
19.02 | 21.84 | 23.92 | 28.16 | |
Average Assets |
615.35 | 629.15 | 655.14 | 700.62 | |
Average Common Equity |
83.31 | 72.65 | 53.90 | 78.19 |
Columns are period end dates